Education
About Us
Working with TipRanks
Follow Us
Isofol Medical AB (DE:5IU)
FRANKFURT:5IU
5IU Stock Chart & Stats
Day’s Range― - ―
52-Week Range€0.05 - €0.30
Previous CloseN/A
Volume0.00
Average Volume (3M)166.00
Market Cap
€21.54M
Enterprise Value€208.94M
Total Cash (Recent Filing)€82.11M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta-0.26
Next Earnings
Nov 12, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding281,107,240
10 Day Avg. Volume0
30 Day Avg. Volume166
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Isofol Medical AB News
5IU FAQ
What was Isofol Medical AB’s price range in the past 12 months?
Isofol Medical AB lowest stock price was €0.05 and its highest was €0.30 in the past 12 months.
What is Isofol Medical AB’s market cap?
Isofol Medical AB’s market cap is €21.54M.
When is Isofol Medical AB’s upcoming earnings report date?
Isofol Medical AB’s upcoming earnings report date is Nov 12, 2025 which is in 85 days.
How were Isofol Medical AB’s earnings last quarter?
Currently, no data Available
Is Isofol Medical AB overvalued?
According to Wall Street analysts Isofol Medical AB’s price is currently Overvalued.
Does Isofol Medical AB pay dividends?
Isofol Medical AB does not currently pay dividends.
What is Isofol Medical AB’s EPS estimate?
Isofol Medical AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Isofol Medical AB have?
Isofol Medical AB has 281,107,240 shares outstanding.
What happened to Isofol Medical AB’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Isofol Medical AB?
Currently, no hedge funds are holding shares in DE:5IU
Company Description
Isofol Medical AB
Isofol Medical AB (publ), a clinical stage biotech company, develops, commercializes, and sells oncology drugs in Sweden and internationally. The company develops arfolitixorin, which is in phase 3 clinical trial for the treatment of advanced colorectal cancer. It has strategic collaborations with Recipharm, Merck & Cie, and Sahlgrenska University Hospital. The company was incorporated in 2008 and is headquartered in Gothenburg, Sweden.
Technical Analysis
Xintela AB
―
IRLAB Therapeutics AB Class A
―
Modus Therapeutics Holding AB
―
Active Biotech AB
―
Bio-Works Technologies AB
―